Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Artrya Limited ( (AU:AYA) ).
Artrya Limited has announced its upcoming Annual General Meeting (AGM) to be held on November 13, 2025, at its office in West Perth, Australia, with a webcast available for shareholders. This meeting is part of Artrya’s ongoing efforts to engage with stakeholders as it continues to commercialize its Salix AI-powered platform for coronary artery disease management, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on developing AI-powered solutions to enhance the detection and management of coronary artery disease. The company offers a proprietary software that analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient diagnosis. Artrya is committed to advancing cardiac care through innovative technology and is actively pursuing regulatory and commercial activities in key international markets.
Average Trading Volume: 942,163
Technical Sentiment Signal: Buy
Current Market Cap: A$534.3M
See more data about AYA stock on TipRanks’ Stock Analysis page.